DD

David Dimeo

Active Director Director DIN 10783638
DIN 10783638 First appointment Sep 2024 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Sep 2024
Shareholding value •••• Premium profile

About David Dimeo

Data last updated:

David Dimeo is a Director at Jamp India Pharmaceuticals Private Limited (since 2024). The company operates in Pharma. Jamp India Pharmaceuticals Private Limited reported revenue of ₹155 Cr (FY 2025).

DIN 10783638
Primary Designation Director
Industry Pharma
First Appointment 27 Sep 2024
Oldest Company Age 9 yrs
Largest company Jamp India Pharmaceuticals Private Limited · ₹155 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director27 Sep 20242017₹155 Cr (FY 2025)Active

Directorship timeline

Open interactive timeline →
Jamp India Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for David Dimeo

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about David Dimeo

David Dimeo currently holds 1 directorship: Jamp India Pharmaceuticals Private Limited (Director, since 27 Sep 2024, revenue ₹155 Cr (FY 2025)).

David Dimeo was first appointed on 27 Sep 2024 as Director at Jamp India Pharmaceuticals Private Limited.

The current boards of David Dimeo's companies include Alpeshkumar Thakkar (Jamp India Pharmaceuticals Private Limited), Marcandre Huot (Jamp India Pharmaceuticals Private Limited), Raveesh Grover (Jamp India Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available